Jump to main content
Jump to site search

Issue 5, 2011
Previous Article Next Article

Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease

Author affiliations

Abstract

We report here the first application of Group 9 metal complexes (i.e.iridium(III) and rhodium(III)) as inhibitors of amyloid fibrillogenesis and as luminescent probes for Aβ1–40peptide. These complexes contained aromatic co-ligands to interact with the hydrophobic residues around the N-terminal domain of the Aβ1–40peptide, as well as solvato co-ligands to allow coordinative bond formation with histidine residues. We demonstrate that these complexes could inhibit Aβ1–40peptide aggregation in vitro, with potency superior to previous metal-based inhibitors reported. Furthermore, we have demonstrated the first example of luminescent detection of Aβ1–40peptides by transition metal complexes.

Graphical abstract: Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease

Back to tab navigation
Please wait while Download options loads

Supplementary files

Publication details

The article was received on 20 Dec 2010, accepted on 02 Feb 2011 and first published on 25 Feb 2011


Article type: Edge Article
DOI: 10.1039/C0SC00636J
Citation: Chem. Sci., 2011,2, 917-921
  •   Request permissions

    Group 9 metal-based inhibitors of β-amyloid (1–40) fibrillation as potential therapeutic agents for Alzheimer's disease

    B. Y. Man, H. Chan, C. Leung, D. S. Chan, L. Bai, Z. Jiang, H. Li and D. Ma, Chem. Sci., 2011, 2, 917
    DOI: 10.1039/C0SC00636J

Search articles by author